They demonstrated that Keap1/Nrf2 pathway promotes PD-L1 expression in the microenvironment from the perspective of metabolism and tumor immune microenvironment, thus providing a new target for lung cancer immunotherapy. Here, NFE2L2 is linked to lung cancer.